1034305-23-1

Basic information

• Product Name: Methyl 1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]-
• Synonyms: Methyl 1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]-;Methyl 1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-alpha-D-glucopyranoside;(2S,3R,4S,5S,6R)-2-(3-(benzo[b]thiophen-2-ylMethyl)-4-fluorophenyl)-6-(hydroxyMethyl)-2-Methoxytetrahydro-2H-pyran-3,4,5-triol;Ipragliflozin impurity A (C7);Methyl 1-C-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-alpha-glucopyranoside;Methyl 1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-α-D-glucopyranoside
• CAS NO: 1034305-23-1
• Molecular Formula: C₂₂H₂₃FO₆S
• Molecular Weight: 434.4778232
• EINECS: -0
• Mol File: 1034305-23-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Methyl 1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]-(1034305-23-1)
• EPA Substance Registry System: Methyl 1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]-(1034305-23-1)

Safety Data

• Hazardous Substances Data: 1034305-23-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]is used as a molecular scaffold for drug development due to its unique molecular structure and the presence of fluorophenyl and benzo[b]thien-2-ylMethyl groups. These groups may confer specific chemical and biological properties that can be exploited in the design of new pharmaceutical agents.
Used in Organic Synthesis:
Methyl 1-C-[3-(benzo[b]thien-2-ylMethyl)-4-fluorophenyl]is used as a building block in organic synthesis. Its complex molecular structure and functional groups make it a valuable component in the synthesis of various organic compounds, potentially leading to the development of new materials and chemical products.

Upstream product

• 67-56-1 methanol 
• 1034305-17-3 2-[(5-bromo-2-fluorophenyl)methyl]-1-benzothiophene 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 

Downstream Products

• 1034305-27-5 methyl 2,3,4,6-tetra-O-acetyl-1-C-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-α-glucopyranoside 

Relevant articles and documents

Preparing methods of ipragliflozin intermediates

The invention discloses preparing methods of ipragliflozin intermediates. The methods includes preparing methods for 2-(3-benzo[B]thien-2-ylmethyl-4-fluorophenyl)-3,4,5-tris(trimethylsiloxy)-6-trimethylsiloxymethyl-tetrahydro-pyran-2-ol (a compound 3) and (1S)-2,3,4,6-tetraacetoxy-1,5-anhydro-1-[3-(1-benzothiophen-2-yl-methyl)-4-fluorophenyl]-D-glucitol (a compound 6). Under the premise of controlling the temperature of a reaction solution to be not higher than -60 DEG C, n-butyllithium should be added dropwise as soon as possible, and the higher the adding speed of the n-butyllithium is, theless F-ortho-position substituted side products of the compound 3 are, thus ensuring purity of the compound 3 and directly influencing the yield of the compound 6 finally prepared. Through scale-up, the methods are free of scale-up effects, and are suitable for industrial production.

C-glycoside derivative method for manufacturing

The subject of this invention is to provide a high efficiency and industrial conditions in order to facilitate manufacturing C-glycoside derivative technology. Use of the aryl magnesium acid salt (aryl magnesate) the coupling reaction, thereby can prevent the ultra-low temperature reaction, and at the same time, can be short time and high-yield manufacturing C-glycoside derivative.

METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND SYNTHETIC INTERMEDIATE THEREOF

The present invention provides a method for producing a C-glycoside derivative, which can produce the C-glycoside derivative at a high yield and at a low cost, which conforms to environmental protection, and which is applicable industrially. The C-glycoside derivative is useful for treating and preventing diabetes such as insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes) and the like and various diabetes-related diseases including insulin-resistant diseases and obesity.